Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Thalia Therapeutics enters new phase of development

Fri 17 Jul 2026 15:20

(Sharecast News) - Thalia Therapeutics said on Friday that it was entering a new phase of development ahead of its annual general meeting, with the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75m fundraising expected to accelerate its transition into a clinical-stage RNA therapeutics company. Subject to shareholder approval, the deal will add miRisten, a Phase 1 microRNA treatment for acute myeloid leukaemia, to the group's pipeline alongside its Nuvec delivery technology and cardiovascular siRNA programme.

The AIM-traded company said the fundraising provides sufficient capital to complete the ongoing Phase 1 study of miRisten, with topline data expected in the first half of 2027, while also advancing its cardiovascular programme towards IND-enabling studies and further developing the Nuvec platform.

Thalia said the expanded portfolio would strengthen its position in oncology and cardiovascular disease, targeting large unmet medical needs.

At 0834 BST, shares in Thalia Therapeutics were down 7.69% at 0.6p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

Share this article

Related Sharecast Articles

Wed 19 Aug 2026 14:30
Oakley Capital Investments acquires enterprise AI data platform Graphwise
(Sharecast News) - London-listed Oakley Capital Investments announced on Wednesday that one of its funds has acquired knowledge graph and semantic data technology firm Graphwise.
Wed 19 Aug 2026 13:55
Target hikes FY outlook after strong Q2 and tariff uplift
(Sharecast News) - Target posted another strong set of quarterly numbers on Wednesday, with tariff refunds giving earnings an additional lift and prompting the retailer to raise its full‑year guidance as its turnaround continued to take hold.
Wed 19 Aug 2026 13:48
Thursday preview: Walmart, Hays, JD Sports results due
(Sharecast News) - On Thursday, UK corporate releases will include full-year results from recruiter Hays and a trading statement from sportswear retailer JD Sports.
Wed 19 Aug 2026 13:45
Moderna, Merck surge on positive trial results for melanoma vaccine
(Sharecast News) - Merck and Moderna surged on Wednesday after the pharmaceutical companies said a personalised mRNA melanoma vaccine they are jointly developing showed positive results in a first-ever late-stage trial.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026